Jesse Goodman - GlaxoSmithKline Plc Non-Executive Director
| GSKN Stock | MXN 655.00 0.00 0.00% |
Director
Dr. Jesse Goodman is NonExecutive Independent Director of the Company since 1 January 2017. Dr Jesse previously served in senior leadership positions at the US Food and Drug Administration, including most recently as the FDAs Chief Scientist and previously as Deputy Commissioner for Science and Public Health and as Director of the Center for Biologics Evaluation and Research . Jesse played a leadership role in developing the FDAs Regulatory Science and Medical Countermeasures Initiatives and has worked collaboratively with industry, academia, government and global public health and regulatory partners to prepare for and respond to major public health threats, including emerging infectious diseases, disasters and terrorism. He led the FDAs response to West Nile Virus and to the 2009 H1N1 influenza pandemic and served on the Senior Leadership Team for the 2010 White House Medical Countermeasure Review. Jesse brings scientific and public health expertise to the Boards deliberations. Jesse, currently Professor of Medicine at Georgetown University, directs the Georgetown University Center on Medical Product Access, Safety and Stewardship and is an active clinician who serves as Attending Physician in Infectious Diseases. He also serves as President and Member of the Board of the United States Pharmacopeia and as a member of the Regulatory Working Group of the Coalition for Epidemic Preparedness Innovations . since 2017.
| Age | 66 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GlaxoSmithKline Plc's management efficiency ratios could be used to measure how well GlaxoSmithKline Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Luis MacKissack | Grupo Sports World | 55 | |
| Melanie Healey | Verizon Communications | 56 | |
| Salvador Aguilar | Grupo Sports World | 55 | |
| David Teatum | Grupo Sports World | N/A | |
| Richard Brissenden | McEwen Mining | 70 | |
| Allen Ambrose | McEwen Mining | 58 | |
| Enrique HernandezPulido | Grupo Sports World | N/A | |
| Emilio Gamboa | Southern Copper | 78 | |
| Wilfrido Mejorada | Grupo Sports World | N/A | |
| Maria Arnal | Grupo Sports World | N/A | |
| Roberto Heredia | Grupo Sports World | N/A | |
| Kathryn Tesija | Verizon Communications | 54 | |
| John Teets | Air Transport Services | 45 | |
| Shellye Archambeau | Verizon Communications | 55 | |
| Arthur Lichte | Air Transport Services | 64 | |
| Andrea Zullo | Grupo Sports World | N/A | |
| Cynthia Ayon | Grupo Sports World | 52 | |
| Gilberto Cifuentes | Southern Copper | 75 | |
| Lina Rodriguez | Grupo Sports World | 39 | |
| Hadi Ibrahim | Grupo Sports World | 42 | |
| Gregory Wasson | Verizon Communications | 58 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GlaxoSmithKline plc Leadership Team
Elected by the shareholders, the GlaxoSmithKline Plc's board of directors comprises two types of representatives: GlaxoSmithKline Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline Plc's management team and ensure that shareholders' interests are well served. GlaxoSmithKline Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vindi Banga, Senior Independent Non-Executive Director | ||
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director | ||
| Daniel Podolsky, Non-Executive Independent Director | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Luc Debruyne, President - Global Vaccines | ||
| Andrew Witty, CEO, Executive Director | ||
| Brian McNamara, CEO - GSK Consumer Healthcare | ||
| Roy Anderson, Non-Executive Independent Director | ||
| Philip Hampton, Independent Non-Executive Director | ||
| Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Vivienne Cox, Non-Executive Director | ||
| Bill Louv, Senior Vice President - Core Business Services | ||
| Diana Conrad, Chief Officer | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Abbas Hussain, President Global Pharmaceuticals | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Hans Wijers, Independent Non-Executive Director | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Stephanie Burns, Non-Executive Independent Director | ||
| Julie Brown, Chief Officer | ||
| Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Deryck Maughan, Senior Independent Non-Executive Director | ||
| Jesse Goodman, Non-Executive Director | ||
| Laurie Glimcher, Non-Executive Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, VP Office | ||
| James Ford, Sr Compliance | ||
| Victoria Whyte, Company Secretary | ||
| Daniel Troy, Sr. VP and General Counsel | ||
| Shah Hussain, President - Europe, Japan & EMAP | ||
| Tony Wood, Chief Officer | ||
| Manvinder Banga, Non-Executive Director | ||
| David Redfern, Chief Strategy Officer | ||
| Patrick Vallance, President - Pharmaceuticals R&D | ||
| Stacey Cartwright, Non-Executive Independent Director | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| Karenann Terrell, Chief Digital & Technology Officer | ||
| Claire Thomas, Senior Vice President - Human Resources |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.79 T | |||
| Shares Outstanding | 2.05 B | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 14.10 % | |||
| Price To Earning | 11.33 X | |||
| Price To Book | 6.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |